- STAT+: BioNTech and Pfizer tout bispecifics data at ASCO, and Pazdur sees silver lining at FDAASCO, Day 2: promising news around lung cancer, new immunotherapies, and bold words from Rick Pazdur.STAT · 1mo ago↗ source
- STAT+: China competition, ‘destruction’ at FDA give agency chance to restructure, Rick Pazdur saysRick Pazdur on the FDA: “We've had a lot of destruction here, and it doesn't mean that we have to just go back and say, well, let's rebuild it as…STAT · 1mo ago↗ source
- STAT+: Revolution Medicines starts shipping experimental pancreatic cancer drugCEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.STAT · 1mo ago↗ source